Sutro Biopharma, Inc. (STRO)
Develops antibody drug conjugates to treat cancer and infectious diseases.
$23.73-0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+193.0%
The outlook
Analysts are solidly bullish on STRO, with a strong buy consensus and an average price target roughly double the current price. The stock sits in the lower-middle portion of its 52-week range and is trading mixed relative to its moving averages, showing neither clear upward nor downward momentum at present.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 12 analysts
Price trendMixed vs its moving averages
52-week range45% of the way from its 52-week low to high
Price targetAvg target +101% vs current price
Analyst price target
~12-month · 12 analysts$47.75average target+101.2% vs now
Now $23.73
Low $10.00High $61.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$393.2M
52-wk high
$43.85
52-wk low
$7.15
50-day avg
$28.59
200-day avg
$20.40
Trailing P/E
—